Echinacea purpurea tincture and method of producing same

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

 

Prior art

The invention relates to chemical-pharmaceutical industry, namely to the infusion of herbs, rhizomes and roots of Echinacea purpurea (L.) Moench, possessing immunomodulating, immunostimulating, antimicrobial, anti-inflammatory and antiviral activity and process for its preparation. The tincture is used to increase the protective and immune properties of the organism and treatment caused by various germs and viruses, infections, flu, colds, recurrent infections of the respiratory tract and other similar diseases.

A number of pharmacological drugs are derived from compounds from various species of plants of the genus Echinacea, and various methods for their manufacture using different parts of plants: roots, flowers and ground units.

The genus Echinacea originates from North America. He belongs to the Asteraceae family (Asteracea) and includes nine species of plants, in particular Echinacea purpurea L. Moench, angustifoliate Echinacea angustifolia D.C., pale Echinacea Pullida Nutt and other Echinacea.

The chemical composition of plants:

- grass purple Echinacea contains polysaccharides (heteroxylan, arabinofuranosyladenine), essential oils (0,15-0,50%), flavonoids, oxycinnamic (cichorieae, chlorogenic, katarova) acid, tannins, saponins, polyamines, ehinatsin, echinodon, ahin�cosid, organic acids, resins, phytosterols;

- the rhizome and roots - inulin (to 5.9%), glucose (7%), essential and fatty oils, carboxylic acids, betaine, resins.

All parts of the plant contain enzymes, macro (potassium, calcium) and trace elements (selenium, cobalt, silver, molybdenum, zinc, manganese, etc.).

Pharmacological activity of Echinacea purpurea (L.) Moench define the following biologically active substances:

- polysaccharides and their monomers, in particular inulin and fructans, which content in the roots can reach 5.9 per cent;

the phenylpropanoids: cichorieae acid (2,3-O-diaferia), katarova and chlorogenic acid, echinacoside (glucoside 2,3-O-dicovering acid, cynarine;

- flavonoids: luteolin, luteolin-7-glucoside, kaempferol and its 3-glucoside and 3-rutinoside, quercetin and its 3-glucoside, 3-xyloside, 3-arabinoside, rutin, and others;

unsaturated carbohydrates (Poliny) included in the composition of essential oils: ehanol (10-E-hydroxy-4,10-dimethyl-4,11-dodecadien-2-he), 1 - pentadecane, 1,8 Z-pentadecane;

- alkylamide unsaturated acids, in particular echinacin (isobutylene of dodeca-2E, 6Z, 8E, 1 OE-tetraenoic acid), isobutylamine of dodeca-2E, 4E, 8Z, 10E-tetraenoic and dodeca-2E, 4E, 8Z, 10Z-tetraenoic acids.

The phenylpropanoids rich ground part of the plant Echinacea purpurea (L.) Moench, and roots contain high concentrations of inulin. It is established that inu�John activates the immune system, increasing the movement of white blood cells to areas that are infected, increasing the solubility of immune complexes and destroying bacteria, viruses and other microorganisms.

All known preparations based on Echinacea have different concentrations extracted from plant substances, and various quantitative and qualitative composition of the extracted substances and compounds that due not only to different parts of the plant Echinacea and different technology for their industrial preparation, in connection with which all known preparations based on Echinacea have different qualitative and quantitative composition, various physical, chemical, and pharmacological properties.

It is known that different processing methods and process conditions have a significant impact on the content and the ratio extracted from plant material substances and compounds and their pharmacological activity (Ants I. A. Technology of drugs. Ed. 3rd, Rev. and add. 1, 2. - M.: Medicine, 1980).

Known drugs "Ehinatsin of liquidum (series 518626, Germany) and Immunal (series 0401195, Slovenia), obtained by pressing of freshly harvested plants and adding 22 or 20% of ethyl alcohol. The technical disadvantage of such technologies is the possibility of precipitation in CBE�eat juice of Echinacea and consequently the need for the regulation of acidity pH below 6 using an acid (patent EP 0920871 A1, A61K 35/78, publ. 09.06.1999).

A method of producing an immunomodulating drug "Tincture of Echinacea purpurea" with the use of ethanol, which, for the purpose of increasing the yield of phenylpropanoids, extraction is carried out three times herbs Echinacea 40% ethanol by maceration method in three extractors at a ratio of raw material: extractant ratio of 1:8, and the first extraction is carried out at room temperature and two followed by heating to 70-80°C for 30 minutes (patent RU 2134584, A61K 35/78, publ. 20.08.99). The disadvantage of this method is the use of elevated temperatures at which decompose valuable biologically active substances.

Also known Echinacea tincture Dr. tice (series 01027, Austria) and its production method (Bauer R., Wagner N. Echinacea: Hand-buch fur Artze Apotheker und andere Naturwissenschaftler. - Stuttgart: Wissenschaftliche Verlagschaft. 1990. - 182 s.; patent RU 2134584, A61K 35/78, publ. 20.08.99). The essence of this method lies in the fact that the herb Echinacea pour extractant (55% ethanol), infused for 7 days, then the extract is drained, the residue several times squeezed and washed extractant and pulled the hoods to the desired volume. As a result of extraction by maceration method get Echinacea tincture Dr. tice with the content of extractives of 0.4%, including phenylpropanoids of 0.02%. Technical�ski disadvantages of tincture of Echinacea Dr. tice and process for its preparation are relatively low content of extractives (0.4%) and target components, the duration of the process (more than 7 days phase extraction), insufficiently high yield of extractives and incomplete extraction of vegetable raw materials.

A method of producing tinctures of Echinacea purpurea obtained water-alcohol extraction of the herb Echinacea purpurea L. 40% ethyl alcohol by fivefold method of percolation with a total ratio of raw material: extractant 1:5 and at a ratio of raw material: extractant at each stage of percolation of 1:1, then mixing the obtained at each stage of percolation extracts and sedimentation resulting mixture of extracts within 1-5 days at a temperature of 8 to 10°C (see EN 2163138 C1, 20.02.2001). The technical disadvantage of this method is the duration and complexity of the technological process, the method does not ensure maximum recovery of all target components of Echinacea purpurea.

A method of producing tinctures of Echinacea purpurea, wherein the extractant used is 40% ethyl alcohol, extraction of the herb Echinacea is carried out by a modified maceration, combining the extraction at room temperature and when heated in the temperature range of 70-80°C (EN 2288732 C1, 10.12.2006). The disadvantages of this method is incomplete extraction of raw materials and, as a consequence, the low yield of the target substances, and the use of those high�of temperature, when destroying valuable biologically active substances.

A method of producing extracts from the rhizomes of Echinacea angustifolia, consisting in the extraction of raw materials first organic extractant with a water content of not more than 40% (V/V), then the organic extractant with a water content of 60% (V/V) and above, the mixing of the extracts obtained in the previous stages (RU 2317095 C2, 20.02.2008). The disadvantage of this method of receipt is insufficient yield of biologically active substances.

A method of obtaining funds from the roots of Echinacea purpurea by extraction of raw materials 50% ethyl alcohol by the method of percolation in six stages (UA 56832 C2, 15.05.2003). The technical disadvantage of this method is the duration and complexity of the process, insufficient yield of biologically active substances.

Closest to the proposed solution is a document (Gordiychuk G. N. The kinetics of the equilibrium at the extraction of the herb Echinacea in the system solid - liquid // Scientific Herald of International Humanitarian University, No. 1, 2010, pp. 31-35) which disclosed the tincture of Echinacea purpurea, obtained by extraction of the herb Echinacea 40% ethanol, twice (or thrice), insisting each time for 10-12 hours, at a ratio of raw material: extractant 1:6, at 40°C. the Disadvantage of this �of p is insufficient to extract all of the desired components of Echinacea purpurea.

Purpose and summary of the invention

The object of the invention is to develop a new technology for producing tinctures from herbs, roots and rhizomes of Echinacea purpurea and creation of medicines based on it.

The technical result consists in obtaining tinctures from different morphological parts of Echinacea purpurea herbs, roots and rhizomes, while maintaining the biological activity of the ingredients included in the composition tinctures, medicinal qualities and properties.

The technical result is achieved by carrying out the method consists in the fact that the crushed roots and rhizomes of Echinacea purpurea (L.) Moench steamed for 3-4 hours, then extracted with 40% ethyl alcohol in the ratio raw: extractant 1:6 at a temperature of 25-30°C, persist for 12-24 hours, then stirred for at least 1 hour, pushing another 12-24 hours, poured the extract, equal to the amount loaded of the roots and rhizomes of Echinacea purpurea (L.) Moench, after draining part of the extract to the treated raw material is added 40% ethyl alcohol in the ratio of raw material: the extractant is 1:1, after 12-24 hours the whole extract is decanted; at the same time extraction of powdered herb Echinacea purpurea (L.) Moench 40% ethyl alcohol in the ratio raw: extractant 1:6 at a temperature of 25-30°C, persist for 12-24 hours, then stirred for at least 1 hour, still insist 12-24 cha�and, poured the extract, equal to the number loaded herb Echinacea purpurea (L.) Moench, after draining part of the extract to the treated grass was added 40% ethyl alcohol in the ratio raw: extractant 1:1, 12-24 hours all the extract is drained; all the obtained extracts were pooled and cooling is carried out for 5-8 days at a temperature of 4-7°C, filtered.

Using this method, get a new immunomodulating, immunostimulating, antimicrobial, anti-inflammatory and antiviral agent, in the form of tinctures from herbs and rhizomes with roots of Echinacea purpurea (L.) Moench, while preserving the biological activity of the components that are part of the stated means of medical qualities and properties.

Get a tincture of herbs and rhizomes with roots of Echinacea purpurea (L.) Moench, contains extractive substances Echinacea purpurea (L.) Moench and ethyl alcohol, with the following ratio of components, vol.%:

extractives the herbs and rhizomes with rootsat least 1.7
Echinacea purpurea (L.) Moench
cichorieae acidOf 0.01-0.1
chlorogenic acidtraces
kaftar�Vaya acid Of 0.01-0.1
inulin0,05-0,9
ethanolnot less than 30

It is experimentally established that as a result of this claimed as the invention of technology produced the extraction of the desired pharmacologically active ingredients - inulin, cichorieae, and the chlorogenic capterboy acids while preserving their biological activity, medicinal qualities and action.

The invention is as follows.

The invention is illustrated below by examples of practical industrial implementation of the invention.

The extractant (40% ethanol) is prepared in a reactor with a stirrer. In the reactor serves 95% ethyl alcohol (FAK 57127, FEF 42-9292-08, CH. 1-4, FS-000490-190213) and there is fed in the required amount of purified water (FS 42-2619-97).

Chopped herbs or rhizomes with roots of Echinacea purpurea (L.) Moench (VFS 42-2371-94, EP7 01/2008:1823 in Spanish 6.0, EP7 01/2008:1824, soloist 6.0, TFS 426672) was charged into two steel basket with a perforated top and bottom, which is placed in the percolator (two baskets in each percolator). Percolator provided with a jacket, to maintain the temperature of maceration in the range of from 25 to 30°C, to the lower pipe percolator is supplied acute �ar to allow steaming of vegetable raw materials loaded into the percolator.

In the first percolator load two baskets of rhizomes and roots of Echinacea purpurea (L.) Moench. The steaming is carried out for from 3 to 4 p.m.

After warming up the rhizomes and roots of Echinacea purpurea (L.) Moench pour in percolator extractant 40% ethyl alcohol in the ratio raw: extractant 1:6 and insist in a closed apparatus at a temperature of from 25 to 30°C for 12-24 h, followed by stirring the contents of the percolator, then continue the infusion for 12-24 hours and spend plums extract from the percolator in the quantity equal to the weight of the loaded material in the intermediate tank. After draining part of the extract, the treated roots and rhizomes was added 40% ethyl alcohol in the ratio raw: extractant is 1:1. Maceration is carried out for 12-24 hours and produce plums just extract obtained in the intermediate tank.

In the second percolator, simultaneously with the first, is charged with two baskets with grass Echinacea purpurea (L.) Moench., pour the extractant 40% ethyl alcohol in the ratio raw: extractant 1:6 and insist in a closed apparatus at a temperature of from 25 to 30°C for 12-24 h, followed by stirring the contents of the percolator, then continue the infusion for 12-24 hours and spend plums extract from the percolator, the number�TVE, equal to the weight of the loaded material in the intermediate tank. After draining part of the extract, the treated grass was added 40% ethyl alcohol in the ratio raw: extractant is 1:1. Maceration is carried out for 12-24 hours and produce plums just extract obtained in the intermediate tank.

All the obtained extracts were pooled in the collection and carry out the cooling and lighting at a low temperature of 4 to 7°C for 5-8 days. Vyhrazena tincture is filtered through a cascade of filters with different pore diameter.

Ready Echinacea tincture serves on packing in bottles of amber glass with screw neck type FC, FBD, EF-30-20, EF-50-20 or EF-100-20 on the EAST 64-2-71-80, sealed with plastic tubes on the EAST 64-2-87-81, GOST 16337-77, THE 64-332-83 and screw-on lids for OST 64-2-87-81, OST 64-2 218-84, THE 9467-003-14552200-2009.

The used raw material is subjected to steaming, in order to recover ethanol from the waste materials, which densely cover the percolator, serves water vapor inside the apparatus. Alcohol distant and condensed in the refrigerator and collected for reuse as the extractant.

Received Echinacea tincture is a clear liquid without foreign inclusions yellowish brown to brown in color density 0,9482-0,9622 g/cm3. Storage allows�I the appearance of floc or precipitate in the form of a black Deposit on the bottom and walls of the vial, which when shaken, broken, or education is not crashing plaque on the bottom and walls of the vial. The presence of sediment is the result of the use of natural raw materials and does not affect the quality of the product.

The concentration of extractives Echinacea purpurea (L.) Moench in the tincture in % by volume: not less than 1.7, including the content cichorieae acid of 0.01-0.1, chlorogenic acid - the tracks, capterboy acid of 0.01-0.1, inulin from 0.05 to 0.9 and the content of ethyl alcohol of not less than 30. The shelf life of tincture 4 years.

Determination of quantitative and qualitative indicators obtained tincture is carried out as follows.

Test 1: 3 ml of the drug is transferred to a test tube with a capacity of 10 ml, add 1 ml of iron oxide chloride 1% and shake: the solution becomes dark green color, when standing falls black precipitate (phenolic compounds).

Test 2: 1 ml of the drug is placed in a volumetric flask with a capacity of 50 ml, adjusted with ethyl alcohol 40% to the label.

10 ml of the resulting solution is transferred to a volumetric flask with a capacity of 50 ml, adjusted with ethyl alcohol 40% to the mark. The contents of the flask are thoroughly mixed (the test solution).

The optical density of the test solution is measured on the spectrophotometer at the maximum absorption at a wavelength of 328 nm in a cuvette with a layer thickness of 10 mm.

The UV spectrum of the prepared Sol�RA of the drug in the region from 200 to 400 nm should have a maximum absorption at wavelength (328±2)nm, low absorption at (265±2) nm and an inflection in the area (300-310) nm.

Test 3: Content of solids in the infusion is determined by the methodology described in the global Fund XI, issue. 2, p. 149. The solids content should be at least 1.7%.

Test 4: To 10 ml of tincture added solutions Carries and Carries 200 μl. The sample was centrifuged at 3000 rpm.mines taken over sedimentary liquid and 10 ál injected into the injector of the chromatograph Varian-920 LC with diagnosticum detector, a column thermostat temperature 35°C, the speed of eluent, 1 ml/min in gradient elution mode in accordance with FS. The content cichorieae acid of 0.01-0.1%, chlorogenic acid - the tracks, capterboy acid of 0.01-0.1%.

Test 5: 20 ml of the tincture is evaporated at 70°C using a vacuum evaporator to 10 ml, add 150 μl of concentrated HCl to pH=2 and hydrolysis is carried out for 40 min. Then added 300 μl of a saturated KOH solution to pH=7. To the resulting solution add solutions Carries and Carries 200 μl, and the solution was centrifuged at 3000 rpm.min, the Obtained supernatant is diluted with water 2 times and 10 μl injected into the injector of the chromatograph Varian-920 LC with diagnosticum detector, a column thermostat temperature 35°C, the speed of eluent, 1 ml/min. test sample prepared similarly without addition of HCl. Inulin content of 0.05 to 0.9%.

Test 6: the Content of ethyl alcohol in on�choice determined by the method described in GF XL, vol. 1, p. 26. The content of ethanol in the tincture should not be less than 30%.

Method of application of Echinacea tincture is as follows.

Inside. Shake before use. Adults and children over 12 years: 25-35 drops 3 times a day before meals. The average duration of treatment is 2-3 weeks.

Accounting and interpretation of results

Experimentally, the proposed infusion does not possess irritating and sensitizing effect and non-toxic.

Immunomodulatory, immunostimulatory, antimicrobial antiviral and anti-inflammatory effect of proposed remedies, characterized by its method of preparation, due to the presence of components of extractives, particularly phenylpropanoids (cichorieae, ferulic, coumaric, caffeic acids, echinacin, echinacoside, etc.), tannins, saponins, flavonoids, carbohydrates (inulin, glucose) and other biologically active compounds.

Study of the effect of Echinacea tincture, obtained on the basis of the proposed method, on phagocytosis in vitro and in vivo have shown that it stimulates 45% hemotoxicity the mobility of granulocytes in the chamber of Boyden, enhances 30-45% the process of absorption of yeast-like fungi Candida albicans by granulocytes and monocytes of healthy donors, however, does not affect nutrilett�th killing phagocytized fungi, and therefore, exhibits immunostimulatory properties.

Also tincture reduces the intensity of inflammation caused applique Croton oil on the skin of the ear of rats decreases the intensity of edema and infiltration of tissue by granulocytes.

Biologically active substances of tincture enhance the phagocytic activity of granulocytes and cells of the RES, induce the synthesis of cytokines and acute phase proteins, stimulate the activity of natural killer cells (NK-cells), which suggests the presence of mediated antimicrobial, anti-inflammatory and antiviral activity. Also the clinical application of tincture of Echinacea purpurea found an increase in activity of lysozyme and complement in the serum of patients.

Thus, our technique of obtaining tinctures from different morphological parts of Echinacea purpurea herbs, roots and rhizomes, allows to obtain a remedy with preservation of biological activity of the components included in the tincture.

1. A method of producing tinctures of Echinacea purpurea (L.) Moench, namely that the crushed roots and rhizomes of Echinacea purpurea (L.) Moench steamed for 3-4 hours, then extracted with 40% ethyl alcohol in the ratio raw: extractant 1:6 at a temperature of 25-30°C, persist for 12-24 hours, then stirred teschenite less than 1 hour, pushing another 12-24 hours, poured the extract, equal to the amount loaded of the roots and rhizomes of Echinacea purpurea (L.) Moench, after draining part of the extract to the treated raw material is added 40% ethyl alcohol in the ratio raw: extractant 1:1, after 12-24 hours the whole extract is decanted; at the same time extraction of powdered herb Echinacea purpurea (L.) Moench 40% ethyl alcohol in the ratio raw: extractant 1:6 at a temperature of 25-30°C, persist for 12-24 hours, then stirred for at least 1 hour, pushing another 12-24 hours, poured the extract, equal to the number loaded herb Echinacea purpurea (L.) Moench, after draining part of the extract to the treated grass was added 40% ethyl alcohol in the ratio raw: extractant 1:1, 12-24 hours all the extract is drained; all the obtained extracts were pooled and cooling is carried out for 5-8 days at a temperature of 4-7°C, filtered.

2. Tincture of Echinacea purpurea (L.) Moench, possessing immunomodulating, immunostimulating, antimicrobial, anti-inflammatory and antiviral activity obtained by the method according to claim 1.

3. Application of the method according to claim 1 for tincture of Echinacea purpurea (L.) Moench, possessing immunomodulating, immunostimulating, antimicrobial, anti-inflammatory and antiviral activity.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing dry propolis. Said method includes grinding raw material, extraction with 96% ethyl alcohol at temperature of +20-25°C using a vacuum-ultrasonic device, filtering, purification from heavy metals and other impurities using a carbon sorbent, followed by evaporation.

EFFECT: disclosed method increases output of biologically active substances and enables purification of propolis from wax, mechanical impurities, high-molecular weight substances, heavy metals and pesticides.

2 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: means represents a dry extract of leaves and flowers of Gratiola officinalis, obtained by milling the leaves and flowers of Gratiola officinalis, extraction with 96% alcohol on a water bath to boiling and boiling, evaporation, dilution of the evaporated residue first with distilled water, then by the addition of chloroform, cooling to room temperature and centrifuging with the following separation of a water fraction and drying it under specified conditions.

EFFECT: means is non-toxic, has an expressed anti-tuberculosis action.

2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: method of producing α(1,2)-L-skeleton-α(1,4)-D-galactopyranosyluronan from Acorus calamus L rhizome is carried out in two steps. At the first step, crushed material is extracted with acidified water and heated on a boiling water bath while periodically mixing; after settling, the mixture is heated once more, left to cool to room temperature and filtered through a multilayer fabric filter; the filtrate is evaporated under a vacuum; the obtained solution is slowly added to 96% ethyl alcohol or to a solution of reclaimed ethanol and left in a cool place to settle the residue, after which the settled solution is drained, and the residue is filtered through a paper filter by successively washing with 96% ethyl alcohol and then with acetone. At the second step, without drying, the residue is transferred from the filter and dissolved in purified water while stirring rapidly; the obtained solution is then centrifuged; the obtained solution is purified from low-molecular weight compounds by filtering through a semi-permeable membrane; the purified solution is frozen and freeze-dried at certain conditions.

EFFECT: improved method.

3 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: method for producing Befungin, a preparation of Chaga mushroom involving extracting the milled raw material in heated water on a heating unit consisting of 3 reactors; adding cobalt salts to the extract in certain environment, mixing with ethanol, evaporating to dry residue of 20-25%.

EFFECT: method enables accelerating the production process, reducing energy demands, improving the quality and completeness of extraction, and improving the quality of the preparation.

2 dwg, 1 tbl, 1 ex

FIELD: aviation.

SUBSTANCE: invention represents the method to obtain the soluble concentrate from sideline products of reindeer antlers, comprising aqueous raw extraction, grounded up to the forced meat condition with particle size of 3-5 mm under the action of ultrasonic vibrations with frequency of 37 kHz with subsequent filtration and vacuum drying at temperature of 45°C and pressure of 0.9 atm, distinguished by the fact that the aqueous raw extraction is carried out at temperature of 35-36°C in the presence of pepsin ferment at its concentration in raw mixture: water of 0.5% during at least 3 hours, at ratio raw: water for tails 1:5, for male genital 1:4, for uteruses with embryos and amniotic fluid 1:2.

EFFECT: significant increase of final concentrate yield from sideline products of reindeer antlers.

3 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to method of simultaneous obtaining of two flavonoids - patuletine and its 7-O-β-D-glucopyranoside - patuletrine. Method consists in the following: milled edge petals of flower of high flavonoid sorts of tagetes patula are extracted with hexane, dried and r-extracted with chloroform, chloroform extract is concentrated, dry residue is dissolved in mixture of petroleum ether - chloroform, precipitated sediment is filtered, washed with petroleum ether and dried, obtained dry powder is dissolved in mixture chloroform - ethanol, precipitated sediment is filtered, washed with petroleum ether and dried with obtaining patuletine. Then, extraction of raw material, which remains after chloroform processing, is carried out with ethanol, alcohol extract is filtered and concentrated, after that, water residue is subjected to liquid phase extraction with ethylacetate, then, organic layer is concentrated, dry residue is dissolved in mixture chloroform - ethylacetate, precipitated sediment is filtered, washed with cooled ethylacetate, solution of hydrochloric acid in ethanol, ethanol and ethylacetate and dried, dry powder is dissolved in mixture ethylacetate-ethanol, precipitated sediment is filtered, washed with ethylacetate and dried with obtaining patuletrine.

EFFECT: method makes it possible to obtain highly pure samples of patuletine and patuletrine, as well as increase target product output.

4 dwg, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing lappaconitine hydrobromide (versions) A method for preparing lappaconitine hydrobromide is implemented by extraction of Aconitum leucostomum root and herb or Aconitum septentrionale root and herb in methylene chloride in a continuous extraction apparatus that is followed by decontamination by means of flash chromatography (version 1), or extraction of a herbal raw material in a polar organic solvent followed by extract removal from the organic solvent (version 2), alkalinisation and extraction of the prepared extract in methylene chloride followed by decontamination of the extract by flash chromatography.

EFFECT: method for preparing lappaconitine hydrobromide provides simplifying the technological process, reducing its length and improving higher yield of the end product of officinal purity.

7 cl, 1 tbl, 9 ex

FIELD: food industry.

SUBSTANCE: method for production of Siberian cedar seeds liqueur (with hepatoprotective, antioxidant, antihypoxic, hypolipidemic effect) by way of maceration with ethyl alcohol usage; whole Siberian cedar seeds are loaded into the reactor, poured with 70% ethyl alcohol water solution; extraction is performed under preset conditions. The medicinal preparation with hepatoprotective, antioxidant, antihypoxic, hypolipidemic effect contains Siberian cedar seeds liqueur. Usage of the medicinal preparation as a hepatoprotective remedy.

EFFECT: liqueur has pronounced hepatoprotective, antioxidant, antihypoxic and hypolipidemic effect.

6 cl, 3 dwg, 8 tbl

FIELD: medicine.

SUBSTANCE: method for producing a pigment complex of bisnaphthazarin for preventing inflammatory diseases, involving demineralising commercial sea urchins' crusts and needles in an organic acid solution, separating organic acid salts and protein, applying pigment solution on a chromatographic column, washing the column with diluted mineral acid and distilled water, eluting the pigment complex, combining fractions containing the pigments, removing ethanol, lyophilising concentrate in the certain environment. The complex of pigments bisnaphthazarins for preventing inflammatory diseases.

EFFECT: complex of pigments prepared by the above method is effective for preventing the inflammatory diseases.

3 cl, 2 dwg, 2 tbl, 4 ex

Vibration extractor // 2545300

FIELD: machine building.

SUBSTANCE: for extraction (leaching) of the substances extracted from the plant materials in food, chemical-pharmaceutical and other industries, for output increasing of the substances extracted from the extractable plant materials and for increasing of their concentration in the ready extraction it is suggested to provide the extractor with the extractant recirculation circuit containing devices for solid phase separation, pump, discharge tank, flowmeter, shutdown valves system, and in the extractor bottom part additionally union will be installed for continuous liquid phase supply.

EFFECT: wider possibility of return in the vessel of part of extraction after solid phase separation in specified ratio with fresh extractant, thus improving conditions of mass exchange due to decreasing of the surface tension of the liquid phase.

1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to means, possessive immunomodulating action. Method of human immunomodulation by application of live suspension of chlorella of strain Chlorella vulgaris IGF No C-111 with concentration 8-10 millions cell/ml in quantity 200 ml per day for adult human.

EFFECT: method makes it possible to increase human immunity effectively.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns an adjuvant immunogenic composition containing meningococcal lipooligosaccharide (LOS) and serotype 14 pneumococcal capsular saccharide (CS14), wherein CS14 contains tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc, while LOS is free from tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc. The group of inventions also concerns a method for inducing the immune response in a mammal involving administering the above composition.

EFFECT: group of inventions provides the stronger immune response to CS14 A as compared to wild-type OMV containing LNnT.

15 cl, 4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing the more effective mosquito puncture procedures for the purpose of treating subclinical mastitis in cows by the effect of mosquitoes on biologically active points. That is ensured by the fact that the exposure covers the biologically active points from both sides of a sacral bone by introducing 20 mosquitoes for 4-5 minutes. The procedures are performed four times every 24 hours.

EFFECT: method provides the clinical effectiveness of 93,3% and is less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day.

EFFECT: method provides the 100% clinical effectiveness in latent mastitis, being less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and concerns an immunostimulant composition containing a compound of formula I; to a method for enhancing the immune response to an antigen in an individual, involving administering the antigen and composition into the individual. Enhancing the immune response can represent enhancing the antibody-mediated immune response, CD4+ T-cell response, CD8+ T-cell response or activating the antigen-presenting cells. What is also presented is a method for enhancing the immune response by administering the antigen and composition containing the compound of formula I intramuscularly.

EFFECT: group of inventions enables achieving enhancing the immune response to the antigen.

24 cl, 7 ex, 13 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a pneumococcal vaccine containing saccharide of 4, 6B, 9V, 14, 18C, 19F and 23F serotypes, separately conjugated with CRM197, and at least one Toll-like receptor-9 (TLR-9) agonist as an adjuvant, wherein the above Toll-like receptor-9 agonist represents CpG-oligonucleotide. Also, the group of inventions concerns using the pneumococcal vaccine for preparing the therapeutic agent for preventing or treating diseases caused by S.pneumoniae; a method for individual's immunisation against the diseases caused by S.pneumoniae infection, involving administering the immunoprotective dose of the vaccine into the above individual.

EFFECT: adding B-class CpG to the conjugated pneumococcal vaccine provides the considerable increase of the proportion of highly responsive patients, good tolerance and cell memory induction in relation to pneumococcal polysaccharides.

45 cl, 9 dwg, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a group if inventions: a pharmaceutical composition, containing immunologically active enantiomer of a component of the cationic lipid R-DOTAP or S-DOTAP, a method of applying the said enantiomer for induction of an immunostimulating adjuvant effect in the immune system, a method of inducing immune response in a patient with applying thereof and a method of treatment or prevention of a disease in the patient by induction of the immunostimulating adjuvant effect by the lipid.

EFFECT: R-DOTAP and S-DOTAP induced production of cytokines IL-2, IL-8, IL-12, chemokines CCL-5, CCL-19 and tumour regression in mice.

23 cl, 15 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: abdominal paracentesis is performed to remove ascetic fluid to be concentrated and filtered by means of hemodialysis filter and plasma filter. The prepared concentrate is added with human recombinant interleukin-2 in a dose of 500 IU. The concentrate is refused intravenously at a perfusion rate of 60 drops a minute in an amount of 500 ml. On the day following the abdominal paracentesis, the concentrate is introduced again.

EFFECT: method provides effective elimination of hypo- and dysproteinemia in the given category of patients, as well as the correction of immune disorders by using plasma self-proteins and cytokines that enables the further surgical correction of the detected pathology.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to immunology, and can be used for obtaining medication for preventive treatment of tuberculosis. Immunotherapeutic medication contains fragments of cell wall of Mycobacterium tuberculosis complex (MTB-C).

EFFECT: claimed medication is obtained by method including the following stages: cultivation of virulent strain of MTB-C for the period, equal or longer than three weeks, and homogenisation of cell culture in presence of non-ionic surface-active substance.

14 cl, 2 ex, 2 tbl

FIELD: food industry.

SUBSTANCE: inventions group relates to food industry. The nutritive composition for improvement of the immune system with a mammal, preferably, with the human includes the following components: (a) at least 18 en% of protein material; (b) at least 12 wt % of leucine of the total quantity of protein material; (c) lipid fraction including at least one ω-3 polyunsaturated fatty acid chosen from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) immunomodulator.

EFFECT: inventions group ensures intensification of protective immune response to an exogenous pathogene or autologous trigger such as neoplastic cells as well as improved humoral immunity or their combination.

17 cl, 4 dwg, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.

EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.

2 cl, 3 dwg, 6 tbl, 6 ex

Up!